NCT01301716View on ClinicalTrials.gov

A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Solid Cancers
Interventions
DRUG

GDC-0980

Oral escalating dose

DRUG

bevacizumab

Intravenous repeating dose

DRUG

carboplatin

Intravenous repeating dose

DRUG

cisplatin

intravenous repeating dose

DRUG

paclitaxel

Intravenous repeating dose

DRUG

pemetrexed

intravenous repeating dose

Trial Locations (5)

28050

Madrid

33612

Tampa

90025

Los Angeles

02114

Boston

02215

Boston

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY